Table 2

Univariable HRs for discontinuing a first TNFi in patients with AS starting a first ever TNFi 1 July 2006 to 31 December 2015, in the nationwide Swedish Rheumatology Quality register

Baseline descriptive dataHR (95% CI)
Age, continuous1.00 (1.00 to 1.01)*
Sex (male vs female)0.61 (0.54 to 0.69)
CRP ≥10 vs.<100.69 (0.60 to 0.79)
BASDAI≥4 vs.<41.79 (1.30 to 2.47)
BASDAI≥4 vs missing1.40 (1.04 to 1.89)
ASDAS, continuous1.14 (1.01 to 1.28)
Peripheral arthritis vs no arthritis1.18 (1.01 to 1.37)
Treatment, reference=not treated
 csDMARD0.92 (0.80 to 1.06)
 NSAID1.04 (0.88 to 1.22)
 Corticosteroids1.08 (0.89 to 1.31)
Type of TNFi
 Etanercept vs infliximab0.64 (0.53 to 0.77)
 Adalimumab vs infliximab0.84 (0.73 to 0.97)
 Golimumab vs infliximab0.79 (0.62 to 0.99)
 Certolizumab pegol vs infliximab0.97 (0.67 to 1.41)
SpA-manifestations, reference=no manifestation
 Anterior uveitis, 0–1.5 years of follow-up0.59 (0.49 to 0.71)
 Anterior uveitis,>1.5 years of follow-up1.08 (0.84 to 1.37)
 Psoriasis1.48 (1.18 to 1.86)
 Inflammatory bowel disease0.91 (0.71 to 1.16)
Comorbidities, reference=no comorbidity
 Cardiovascular disease1.24 (1.08 to 1.43)
 Affective disorder1.81 (1.54 to 2.13)
 Chronic lung disease1.49 (1.22 to 1.82)
 Malignancy1.36 (1.06 to 1.74)
 Diabetes1.36 (0.99 to 1.87)
 Chronic kidney disease0.79 (0.41 to 1.52)
Socioeconomic factors
 Tertiles of annual household income
 Second vs first tertile0.98 (0.83 to 1.17)
 Third vs first tertile0.75 (0.62 to 0.90)
 Fourth vs first tertile0.63 (0.52 to 0.77)
Formal education
 10 to 12 years vs ≤9 years1.06 (0.87 to 1.28)
 ≥13 years vs ≤9 years0.84 (0.68 to 1.03)
Percentage of sick leave/disability pension†
 1%–49% vs no1.47 (1.25 to 1.73)
 50%–99% vs no1.74 (1.42 to 2.12)
 100% vs no2.01 (1.65 to 2.44)
  • * p value<0.001.

  • †Net days of sick leave or disability pension during 1 year before start first TNFi.

  • AS, ankylosing spondylitis; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity iIndex; CRP, C-reactive protein; NSAID, non-steroidal anti-inflammatory drug; SpA, spondyloarthritis; TNFi, tumour necrosis factor alpha inhibitor; csDMARD, conventional synthetic disease modifying anti-rheumatic drugs.